Erytech Pharma SA (ERYP) News

Headed for good week

Hmmmm their gunna fill the gap
Just news on the street

ERYP...WHAT A BEAUTY AND NOBODYS TALIKING!!!

ERYP ...MINI MONSTER

LOW FLOAT ACTION

French mother ticker up 24% charting strong with 2hrs left in its trading day,6.75Xs ave vol should be really good for us as many of them will be buying here also

ERYP...TRIGGER ON THE ASK IN PRE....

French ticker opened and ran up 18% so far ,$1.04 ,future looks good

French ticker closed up 22.53%,held up good so i expect usa about same or better,its nice to have a sneek peak into the future, French market (+6hrs ahead) opens 3am est

up .055 on only a few trades,wow ERYP turned loose,not seeing tons of naked shorting like most tickers lately

up 200% on steady climb,accumulation all month,last day of month 10Xs ave vol.,most contracts/deals have e o m deadlines,appears something good maybe occurred and insiders loading before news release,the European ticker is up 40% today

12 patents applied,5 granted so far,last one oct 4th,patents have value if big drug wants/needs them

with 10Xs ave vol today and mkt just opened,makes us believe something coming,setting off scanners and getting attention for sure

buyout news expected,greed says $20-$30pps (ppl comparing to another that ran to $90)

thru the 200ma,running parabolic now

Shares Outstanding 31.02M,Shares Float 30.54M,Institutional Ownership 4.80%,Short Float 0.23%

ERYP...LOW FLOATER FLIES AFTER 1.10

ERYP....moves on air!!!

Fillings !!!!

https://www.globenewswire.com/news-release/2022/04/28/2431947/0/en/ERYTECH-Announces-Filing-of-2021-Universal-Registration-Document-and-2021-Annual-Report-on-Form-20-F-as-well-as-its-2022-financial-calendar.html

Read their fillings

that's all you have to say, where's the info that you get regarding ERYP $5 cash/sh??? It's not about me believing, its about what the facts truly are...and where the facts are posted...

You believe what you want.

Finviz is showing ERYP @ 1.74 cash/sh something I'm missing???

Sh!t happens they have $5 a share in CASH!
Buying more on this sell off.

The trial did not meet its primary endpoint of overall survival...

Expecting Phase 3 data readout in early Q4

They are suppose to file for FDA approval in
4th Q

$ERYP interesting

WEBINAR ON ERYASPASE IN PANCREATIC CANCER (SEPTEMBER 1, 2021)

ERYTECH TO PARTICIPATE IN THE CITI 16TH ANNUAL BIOPHARMA CONFERENCE
(September 8 2021 through September 10, 2021)

ERYTECH HOSTING KEY OPINION LEADER WEBINAR ON ERYASPASE IN PANCREATIC CANCER
ERYTECH Hosting Key Opinion Leader Webinar on Eryaspase in Pancreatic Cancer
(September 1 2021)

ERYTECH GRANTED U.S. FDA FAST TRACK DESIGNATION FOR ERYASPASE IN HYPERSENSITIVE ALL
(July 29, 2021)

Erytech is starting the push for sales, fda approval by the end of the month if not sooner. After fda approval eryteck will hit the ceiling.

Look for a quick run above 8 today by close

little action...

$ERYP be ready get some imo

$ERYP next week we rock!!!

$ERYP jumped back in yesterday looks like might run soon

Boiler I’m in I’m getting the feeling it’s gonna rip ..

This would be a great short play if we all shortages together

Sold for a loss volume and interest dried up. Good luck

Somebody nose something I hope. Lol

On radar That’s for sure how the heck this hit $20.00 last week?

Good! Let’s partaaay!

Thinking about getting back in this you guys think news is close?

I agree. EYRP is my favorite to watch for the next 2 weeks after Thursdays huge news and going into the conference read this. We should see much higher moves above $10.00 in the next 2 weeks IMO.
Cambridge, MA (U.S.) and Lyon (France), July 27, 2021 --ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Chief Executive Officer, Gil Beyen, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on August 9th.

BTIG Virtual Biotechnology Conference -- August 9- 10, 2021

Gil Beyen, Chief Executive Officer, will be participating in a fireside chat on Monday, August 9(th) at 9:30am (ET) as well as one-on-one meetings.

If you are interested in arranging a one-on-one meeting, please contact your conference representative.

About ERYTECH and eryaspase

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS(R) platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH's primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.

The Company's lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cells' altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of triple-negative breast cancer. An investigator sponsored Phase 2 trial (IST) in acute lymphoblastic leukemia recently reported positive results, and a Phase 1 IST in 1L advanced pancreatic cancer is ongoing.

Eryaspase received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of advanced pancreatic cancer. The FDA and the European Medicines Agency have granted eryaspase orphan drug status for the treatment of pancreatic cancer and ALL.

ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France, and for patients in the United States at its GMP manufacturing site in Princeton, New Jersey, USA. Eryaspase is not an approved medicine.

ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

For more information, please visit www.erytech.com

CONTACTS

ERYTECH LifeSci Advisors, LLC NewCap Mathilde Bohin /
Eric Soyer Corey Davis, Ph.D. Louis-Victor Delouvrier
CFO & COO Investor relations Investor relations Nicolas
Merigeau Media relations
+1 (212) 915 2577
+33 4 78 74 44 38 cdavis@lifesciadvisors.com +33 1 44 71 94 94
investors@erytech.com erytech@newcap.eu


Attachment
-- ERYTECH_PR_BTIG Conference curtain raiser_EN_vf

> Dow Jones Newswires

July 27, 2021 01:30 ET (05:30 GMT)

I agree. EYRP is my favorite to watch for the next 2 weeks after Thursdays huge news and going into the conference read this. We should see much higher moves above $10.00 in the next 2 weeks IMO.
Cambridge, MA (U.S.) and Lyon (France), July 27, 2021 --ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Chief Executive Officer, Gil Beyen, will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on August 9th.

BTIG Virtual Biotechnology Conference -- August 9- 10, 2021

Gil Beyen, Chief Executive Officer, will be participating in a fireside chat on Monday, August 9(th) at 9:30am (ET) as well as one-on-one meetings.

If you are interested in arranging a one-on-one meeting, please contact your conference representative.

About ERYTECH and eryaspase

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS(R) platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH's primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.

The Company's lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cells' altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of triple-negative breast cancer. An investigator sponsored Phase 2 trial (IST) in acute lymphoblastic leukemia recently reported positive results, and a Phase 1 IST in 1L advanced pancreatic cancer is ongoing.

Eryaspase received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of advanced pancreatic cancer. The FDA and the European Medicines Agency have granted eryaspase orphan drug status for the treatment of pancreatic cancer and ALL.

ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France, and for patients in the United States at its GMP manufacturing site in Princeton, New Jersey, USA. Eryaspase is not an approved medicine.

ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

For more information, please visit www.erytech.com

CONTACTS

ERYTECH LifeSci Advisors, LLC NewCap Mathilde Bohin /
Eric Soyer Corey Davis, Ph.D. Louis-Victor Delouvrier
CFO & COO Investor relations Investor relations Nicolas
Merigeau Media relations
+1 (212) 915 2577
+33 4 78 74 44 38 cdavis@lifesciadvisors.com +33 1 44 71 94 94
investors@erytech.com erytech@newcap.eu


Attachment
-- ERYTECH_PR_BTIG Conference curtain raiser_EN_vf

> Dow Jones Newswires

July 27, 2021 01:30 ET (05:30 GMT)

What news might that be?

IF the float is still 14 million heading into the close and AH something’s gotta give maybe Monday morning. a 14 divisor this close to the close . Sounds goofy doesn’t it but works for me better than half the time Call it a hunch. Boteet! GL!

Why did you think 56m shares traded was magical?

LOL!

Who has more fun than a bunch of fools right? lol

Time to test your theory ;)

ERYP is getting ripe 56 milly and we start rockin!!